Natural history of hepatitis B

Slides:



Advertisements
Similar presentations
1. Interpret a positive HBeAg, Anti- HBcAg, and/or anti-HCV test.
Advertisements

1 Hepatitis B Treatment Dr R.V.S.N.Sarma., M.D., Consultant Physician & Chest Specialist.
1. Sustained suppression of HBV replication Decrease in serum HBV DNA to
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Hepatitis B virus infection in renal transplant recipients
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
Viral Hepatitis.
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B : A Randomized International Study of Entecavir.
(A) Serum antibody and antigen levels in hepatitis A and hepatitis B
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Volume 139, Issue 2, Pages (August 2010)
Volume 50, Issue 4, Pages (April 2009)
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies  Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.
(A) Serum antibody and antigen levels in hepatitis A and hepatitis B
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection  Yi–Cheng Chen, I.–Shyan Sheen,
Volume 67, Issue 2, Pages (August 2017)
Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”
Chronic viral hepatitis type B with “ground glass” cells
Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B 
Volume 61, Issue 6, Pages (December 2014)
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Hepatitis Primary Care: Clinics in Office Practice
Suna Yapali, Nizar Talaat, Anna S. Lok 
Stephanos J. Hadziyannis  Journal of Hepatology 
Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results  Bruno Roche, Didier Samuel  Journal.
Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective.
Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection  Y.W.
Introduction The American Journal of Medicine
Volume 69, Issue 2, Pages (August 2018)
Volume 44, Pages S19-S24 (January 2006)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Reply to: “Low free T3 levels are related to early mortality in patients with decompensated cirrhosis and acute-on chronic liver failure”  Rakhi Maiwall,
Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C  Chi–Jen Chu, Munira Hussain,
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
F. Li, P. Zhou, W. Deng, J. Wang, R. Mao, Y. Zhang, J. Li, J. Yu, F
A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study  M.-C. Tsai,
Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma  Rohit.
Volume 133, Issue 5, Pages (November 2007)
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
L. -W. Song, P. -G. Liu, C. -J. Liu, T. -Y. Zhang, X. -D. Cheng, H. -L
Volume 70, Issue 1, Pages (January 2019)
Volume 139, Issue 2, Pages (August 2010)
Hepatitis C Virus Infection in the Older Patient
Volume 62, Issue 3, Pages (March 2015)
Navigating the Maze of Hepatitis B Treatments
Ming-Ling Chang, Yun-Fan Liaw  Journal of Hepatology 
Volume 120, Issue 4, Pages (March 2001)
Genomic risk of hepatitis C-related hepatocellular carcinoma
Autophagy in the liver Journal of Hepatology
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
Chronic Hepatitis B Virus Carriers in the Immunotolerant Phase of Infection: Histologic Findings and Outcome  Tony Andreani, Lawrence Serfaty, Djamila.
Volume 42, Issue 4, Pages (April 2005)
Volume 67, Issue 5, Pages (November 2017)
Volume 50, Issue 4, Pages (April 2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Volume 67, Issue 5, Pages (November 2017)
Progression of chronic Hepatitis B From beginning to end
Evolution of liver transplantation for hepatocellular carcinoma
Volume 63, Issue 1, Pages (July 2015)
Chronic hepatitis B in children and adolescents
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
HEPATITIS B VIRUS ; WHAT`S NEW
Chimeric mouse model of hepatitis B virus infection
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection  Yi–Cheng Chen, I.–Shyan Sheen,
The metabolomic window into hepatobiliary disease
Scott K. Fung, Anna S.F. Lok  Clinical Gastroenterology and Hepatology 
Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients  D. He, S. Guo, P. Zhu, S. Tao, M. Li,
Presentation transcript:

Natural history of hepatitis B Giovanna Fattovich  Journal of Hepatology  Volume 39, Pages 50-58 (January 2003) DOI: 10.1016/S0168-8278(03)00139-9

Fig. 1 Natural course of HBV infection. The initial immunotolerant phase with HBeAg positivity and high levels of serum HBV-DNA is followed by the immunoactive phase with a decrease in serum HBV-DNA and increase in ALT levels and finally by the non-replicative or minimally replicative phase with seroconversion to antibody to HBeAg (anti-HBe) and remission of liver disease. Reactivation of HBV and of liver disease activity may occur after seroconversion from HBeAg to anti-HBe. Resolved hepatitis B involves loss of HBsAg and seroconversion to HBsAg (anti-HBs). Journal of Hepatology 2003 39, 50-58DOI: (10.1016/S0168-8278(03)00139-9)

Fig. 2 Cumulative incidence of HCC and decompensation (A); and cumulative probability of survival and survival after the appearance of the first episode of decompensation (B) in 161 untreated Caucasian patients with compensated cirrhosis due to hepatitis B [87]. The 5-year rate of HCC and decompensation was 9 and 16%, respectively. The 5-year probability of survival and survival after decompensation was 86 and 28%, respectively. The number of patients under observation refers to the survival probability. Journal of Hepatology 2003 39, 50-58DOI: (10.1016/S0168-8278(03)00139-9)